Janssen gets EC authorisation for DARZALEX SC to treat multiple myeloma
Johnson & Johnson’s pharmaceutical business Janssen has received the European Commission (EC) marketing authorisation for DARZALEX (daratumumab) subcutaneous (SC) formulation to treat multiple myeloma (MM). The new DARZALEX